Careers  |  Sign In  |  Register

GSK Ebola Vaccine Advancing to Phase II in Trials

According to Reuters, GlaxoSmithKline’s experimental Ebola vaccine will be moving to the second phase of its trial and expanding to several additional countries in February 2015. Currently undergoing Phase I trials in the U.S., Switzerland, Britain and Mali. Additional trials are set to begin in Cameroon, Ghana, Mali, Nigeria and Senegal, provided all requirements are met in concluding the initial phase. Other vaccines for the Ebola virus include serums from NewLink Genetics and Johnson & Johnson.

Read the article published by Reuters.